Form 13-F position report

ESPERION THERAPEUTICS INC NE

Reported by ALLIANCEBERNSTEIN L P

ESPR CUSIP 29664W105 Manager CIK 0001109448

Reported 0 shares, down 3,587,702 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2026
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 10 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 142000
2022-03-31 131000
2022-06-30 234000
2022-09-30 288000
2022-12-31 340158
2023-03-31 116070
2023-06-30 0
2024-06-30 404284
2024-09-30 300482
2024-12-31 350372
2025-03-31 229334
2025-06-30 275396
2025-09-30 561164
2025-12-31 968512
2026-03-31 968512
2026-06-30 9830303
2026-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

17 quarters
Quarterly reported position history for ESPERION THERAPEUTICS INC NE held by ALLIANCEBERNSTEIN L P.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 0 -3,587,702 (-100.0%) 0 $0 2026-11-16
Q2 2026 Added 3,587,702 +3,325,942 (1270.6%) < 0.01% $9,830,303 2026-08-14
Q1 2026 Unchanged 261,760 0 (0.0%) < 0.01% $968,512 2026-05-15
Q4 2025 Added 261,760 +50,000 (23.6%) < 0.01% $968,512 2026-02-17
Q3 2025 Reduced 211,760 -68,000 (-24.3%) < 0.01% $561,164 2025-11-14
Q2 2025 Added 279,760 +120,500 (75.7%) < 0.01% $275,396 2025-08-14
Q1 2025 Unchanged 159,260 0 (0.0%) < 0.01% $229,334 2025-05-15
Q4 2024 Reduced 159,260 -22,850 (-12.5%) < 0.01% $350,372 2025-02-12
Q3 2024 Unchanged 182,110 0 (0.0%) < 0.01% $300,482 2024-11-14
Q2 2024 New 182,110 +182,110 (0.0%) < 0.01% $404,284 2024-08-14
Q2 2023 Reduced 0 -73,000 (-100.0%) 0 $0 2023-08-15
Q1 2023 Added 73,000 +18,400 (33.7%) < 0.01% $116,070 2023-05-15
Q4 2022 Added 54,600 +11,647 (27.1%) < 0.01% $340,158 2023-02-15
Q3 2022 Added 42,953 +6,153 (16.7%) < 0.01% $288,000 2022-11-15
Q2 2022 Added 36,800 +8,500 (30.0%) < 0.01% $234,000 2022-08-15
Q1 2022 Unchanged 28,300 0 (0.0%) < 0.01% $131,000 2022-05-13
Q4 2021 Reduced 28,300 -270 (-0.9%) < 0.01% $142,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

188 managers reported ESPERION THERAPEUTICS INC NE for Q3 2026.

Managers reporting ESPERION THERAPEUTICS INC NE in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Allworth Financial LP Unchanged 2,343 0 < 0.01% $7,404 6 qtrs
GLENMEDE TRUST CO NA New 134 +134 < 0.01% $355 1 qtr
THE BANK OF NEW YORK MELLON CORPORATION Reduced 0 -732,616 0 $0 53 qtrs
GAMMA Investing LLC Reduced 0 -141 0 $0 4 qtrs
GLAZER CAPITAL LLC Reduced 0 -22,416,339 0 $0 2 qtrs
ProShare Advisors LLC Reduced 0 -160,493 0 $0 9 qtrs
XPONANCE INC Reduced 0 -24,094 0 $0 10 qtrs
PSquared Asset Management AG Reduced 0 -3,300,000 0 $0 2 qtrs
MetLife Investment Management LLC Reduced 0 -148,375 0 $0 10 qtrs
Cetera Investment Advisers Reduced 0 -23,237 0 $0 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.